PMID- 34524227 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20230727 IS - 1728-7731 (Electronic) IS - 1726-4901 (Linking) VI - 85 IP - 1 DP - 2022 Jan 1 TI - Consensus statement and recommendations on the treatment of COVID-19: 2021 update. PG - 5-17 LID - 10.1097/JCMA.0000000000000617 [doi] AB - Many treatments including antiviral and non-antiviral drugs, and critical care are considered for the management of coronavirus disease 2019 (COVID-19). Practice recommendations need to be updated and graded according to the critical evaluation of rapidly emerging literature. In June 2020, Research Center for Epidemic Prevention-National Yang Ming Chiao Tung University formed a task group comprising infectious disease clinicians, pulmonologists, and intensivists with varied areas of expertise. The steering committee prioritized questions and outcomes. The keywords for the searches were COVID-19 and prone position, extracorporeal membrane oxygenation (ECMO), noninvasive positive pressure ventilation (NIPPV), remdesivir, lopinavir, hydroxychloroquine/chloroquine (HCQ/CQ), azithromycin, corticosteroid, tocilizumab, convalescent plasma therapy, and intravenous immunoglobin (IVIG). A systematic review of peer-reviewed literature was performed by the consensus panel. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used in assessing the certainty of evidence and making recommendations. The effects of COVID-19 treatments on mortality and clinical improvement were summarized in 11 tables, and GRADE was presented to define the strength and quality of evidence for recommendation. The consensus recommended that prone position implanted in COVID-19 patients with hypoxic respiratory failure (IIC), careful selection for the support of ECMO (IIB), NIPPV being feasible but a risk of staff contamination (IIC), remdesivir generally administered in mild-to-moderate COVID-19 patients (IA), the use of dexamethasone in critically ill COVID-19 patients (IA), and the use of tociliziumab in hospitalized severe/critical COVID-19 patient with elevated markers of systemic inflammation (IA). The consensus recommended against the use of lopinavir/ritonavir (IB), HCQ/CQ (IA), azithromycin (IA), convalescent plasma therapy (IA), and IVIG (IA). The inception of the consensus and task group has provided much-needed evidence of the efficacy and safety of various therapies for the management of COVID-19 patients, and make a description about the benefits and harms for most treatments. CI - Copyright (c) 2021, the Chinese Medical Association. FAU - Ko, Hsin-Kuo AU - Ko HK AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Yu, Wen-Kuang AU - Yu WK AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Department and Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Pan, Sheng-Wei AU - Pan SW AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Chen, Wei-Chih AU - Chen WC AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Yang, Kuang-Yao AU - Yang KY AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Lin, Yi-Tsung AU - Lin YT AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Division of Infectious Disease, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. FAU - Wang, Fu-Der AU - Wang FD AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. AD - Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Yang, Muh-Hwa AU - Yang MH AD - Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. FAU - Chen, Yuh-Min AU - Chen YM AD - Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. CN - Research Center for Epidemic Prevention-National Yang Ming Chiao Tung University (RCEP-NYCU) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 RN - 0 (Antiviral Agents) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulins, Intravenous) SB - IM MH - Antiviral Agents/therapeutic use MH - COVID-19/diagnosis/mortality/*therapy MH - COVID-19 Vaccines/immunology MH - Consensus MH - Extracorporeal Membrane Oxygenation MH - Humans MH - Immunization, Passive MH - Immunoglobulins, Intravenous/therapeutic use MH - Prone Position MH - *SARS-CoV-2 MH - Vaccination MH - COVID-19 Serotherapy EDAT- 2021/09/16 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/09/15 12:31 PHST- 2021/09/16 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/09/15 12:31 [entrez] AID - 02118582-202201000-00003 [pii] AID - 10.1097/JCMA.0000000000000617 [doi] PST - ppublish SO - J Chin Med Assoc. 2022 Jan 1;85(1):5-17. doi: 10.1097/JCMA.0000000000000617.